LCK and breast cancer: We can see that BC patients in Cluster 1 were sensitive to A.770041 (Lck inhibitor), AZD.0530 (Saracatinib), CGP.60474 (CDK inhibitor), NVP.TAE684 (ALK inhibitor), Parthenolide, WH.4.